Table 2.
First- and Second-Line Treatment Patterns for patients with EGFRm+ mNSCLC
| Treatment | |
|---|---|
| Time from NSCLC diagnosis to treatment initiation, weeks | N = 162 |
| Mean (SD) | 5 (19.5) |
| Median (IQR) | 2 (1–3) |
| First-line treatment | N = 162 |
| Monotherapy, n (%) | |
| EGFR-TKI | 144 (88.9) |
| First-generation | 67 (41.4) |
| Gefitinib | 46 (28.4) |
| Erlotinib | 21 (13.0) |
| Second-generation | |
| Afatinib | 71 (43.8) |
| Third-generation | |
| Osimertinib | 6 (3.7) |
| Immunotherapy | 1 (0.6) |
| Combination therapy, n (%) | |
| Chemotherapya | 13 (8.0) |
| EGFR-TKIb | 4 (2.5) |
| Primary reason for selecting 1L treatmentc, n (%) | |
| Efficacy | 137 (84.6) |
| Tolerability | 20 (12.3) |
| Cost (reimbursement status) | 5 (3.1) |
| 1L treatment status at time of data abstraction, n (%) | |
| Still on treatment | 88 (54.3) |
| Died during treatment | 1 (0.6) |
| Discontinued, no subsequent treatment | 15 (9.3) |
| Discontinued, received subsequent treatment | 58 (35.8) |
| Reasons for discontinuation of 1L therapy, n (%) | N = 74 |
| Disease progression | 60 (81.0) |
| Toxicity or adverse effect | 5 (6.8) |
| Patient/clinician decisions | 2 (2.7) |
| Death | 1 (1.4) |
| Completed treatment course as planned | 1 (1.4) |
| Other | 1 (1.4) |
| Unknown | 4 (5.4) |
| Median (IQR) duration of 1L treatmentd, weeks | NA (35.0–NA) |
| Second-line treatment | N = 58 |
| Monotherapy, n (%)e | |
| EGFR-TKI | 33 (56.9) |
| First-generation | 8 (13.8) |
| Erlotinib | 5 (8.6) |
| Gefitinib | 3 (5.2) |
| Second-generation | |
| Afatinib | 2 (3.4) |
| Third-generation | |
| Osimertinib | 23 (39.7) |
| Chemotherapy | 14 (24.1) |
| Pemetrexed | 12 (20.7) |
| Gemcitabine | 2 (3.4) |
| Combination therapy, n (%) | |
| Chemotherapyf | 6 (10.3) |
| EGFR-TKI plus chemotherapyg | 3 (5.2) |
| Primary reason for selecting 2L treatmentc, n (%) | |
| Efficacy | 48 (82.8) |
| Tolerability | 5 (8.6) |
| Cost (reimbursement status) | 5 (8.6) |
| Ongoing at time of data abstraction | 32 (55.2) |
| Reasons for discontinuation of 2L therapy, n (%) | N = 26 |
| Disease progression | 16 (61.5) |
| Patient/clinician decision | 2 (7.7) |
| Death | 1 (3.8) |
| Lost to follow-up | 1 (3.8) |
| Completed treatment course as planned | 1 (3.8) |
| Unknown | 5 (19.2) |
| Median (IQR) duration of 2L treatmenth, weeks | 36.0 (14.0–NA) |
1L first-line, 2L second-line, CI confidence interval, EGFR epidermal growth factor receptor, IQR interquartile range, N total number of subjects, n number of subjects per category, TKI tyrosine kinase inhibitor
aCisplatin + gemcitabine: 4 (2.5%); cisplatin + pemetrexed: 4 (2.5%); carboplatin + docetaxel: 2 (1.2%); carboplatin + gemcitabine: 2 (1.2%); cisplatin + docetaxel: 1 (0.6%)
bGefitinib + osimertinib: 2 (1.2%); afatinib + osimertinib: 1 (0.6%); erlotinib + gefitinib 1 (0.6%)
cPhysicians were required to choose 1 of 4 options: efficacy, tolerability, cost, or other, representing the primary reason for selecting 1L treatment
dFour patients who discontinued 1L treatment had an unknown duration of treatment. Median duration of treatment was calculated based on 70 of 74 patients with known duration of treatment
eOnly categories with >3% patients are included
fCisplatin + pemetrexed: 4 (6.9%); cisplatin + gemcitabine: 1 (1.7%); cisplatin + paclitaxel + pemetrexed: 1 (1.7%)
gAfatinib + docetazel: 1 (1.7%); osimertinib + cisplatin + pemetrexed: 1 (1.7%); osimertinib + docetaxel + gemcitabine + pemetrexed: 1 (1.7%)
hFive patients who discontinued 2L treatment had an unknown duration of treatment. Median duration of treatment was calculated based on 53 of 58 patients with known duration of treatment